Calgary – October 12, 2026 -- XORTX Therapeutics Inc. has re-engaged IR Agency LLC for investor relations and marketing services, following completion of its voluntary delisting from the TSX Venture Exchange.
XORTX restores IR Agency LLC consulting agreement on previously disclosed terms
The new consulting agreement carries substantially the same terms the company disclosed in news releases dated May 19, 2026 and August 28, 2026. The source gives no fee, share-based compensation or contract-length figures for the renewed engagement.
Delisting from TSX Venture Exchange precedes the renewed marketing push
The re-engagement comes after XORTX completed the delisting it had announced earlier. The company's filings reference ongoing compliance with Nasdaq listing standards, and its release states that Nasdaq has not approved or disapproved its contents.
XORTX's lead program is XRx-026 for the treatment of gout. The pipeline also includes XRx-008 for ADPKD and XRx-101 for acute kidney and other acute organ injury associated with respiratory virus infections.
Company flags campaign effectiveness and Nasdaq compliance as risks
XORTX's forward-looking statements cover the services to be provided under the agreement, the anticipated duration of the engagement and the news distribution campaigns the agreement contemplates. The company lists the effectiveness and results of the investor relations and marketing program among the risks that could cause actual outcomes to differ materially. It also cites ongoing Nasdaq listing compliance and the risks described in its filings with the U.S. Securities and Exchange Commission and Canadian securities regulators.